EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieMultizentrische StudieOpen Access

Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma

DIAMOND Study Group, Cheng Xu, Xiao-Yu Liang, Xin-Qiong Huang, Feng Jin, Kun-Yu Yang, Guang-Yuan Hu, Xiao-Dong Zhu, Ying Wang, Ying Huang, Ning Zhang, De-Sheng Hu und 48 weitere

JAMA · 16.09.2025 · 334 (11) · 973

DOI: 10.1001/jama.2025.13205 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 16.09.2025. Verfasst von DIAMOND Study Group und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance With the programmed cell death protein 1 (PD-1) blockade toripalimab, omitting highly toxic concurrent cisplatin may be feasible for nasopharyngeal carcinoma (NPC) without compromising survival.

Objective

To evaluate the efficacy and safety of toripalimab incorporated into induction chemotherapy and radiotherapy, without concurrent cisplatin, for locoregionally advanced NPC. Design, Setting, and Participants Open-label, multicenter, randomized phase 3 clinical trial conducted from August 2021 to July 2022 at 13 hospitals in China, enrolling 532 patients with T4N1M0 or T1-4N2-3M0 NPC; 400 (75.2%) completed the trial per protocol. The final date of follow-up was March 21, 2025.

Interventions

Patients were randomly assigned to either the standard therapy group (n = 266), receiving toripalimab with gemcitabine-cisplatin induction chemotherapy and concurrent cisplatin-radiotherapy (100 mg/m 2 triweekly for 2 cycles), or the concurrent cisplatin–sparing group (n = 266), receiving the same regimen without concurrent cisplatin. The 17 cycles of toripalimab (240 mg triweekly) were distributed across the induction, radiotherapy, and adjuvant phases as 3, 3, and 11 cycles, respectively. Main Outcomes and Measures Coprimary end points were failure-free survival (noninferiority margin, 8%) and incidence of all-grade vomiting (superiority design). Secondary end points included overall survival, locoregional recurrence-free survival, distant metastasis–free survival, safety, tumor response, quality of life, and tolerability.

Results

In the 532 patients in the intention-to-treat population (median [IQR] age, 47 [39-54] years; 25.2% women), after a median follow-up of 37.0 (range, 4.0-50.0) months, the concurrent cisplatin–sparing group had a 3-year failure-free survival rate of 88.3% vs 87.6% in the standard therapy group, a difference of 0.7% (lower limit of the 1-sided 95% CI, −3.9%; P = .002 for noninferiority; stratified hazard ratio, 0.92 [95% CI, 0.66-1.79]; log-rank P = .73). In the safety analysis, the incidence of all-grade vomiting was significantly lower in the concurrent cisplatin–sparing group vs the standard therapy group (26.2% [68/260] vs 59.8% [156/261]; difference, 33.6% [1-sided 95% CI, 26.9%-∞]; P < .001). Patient-reported quality of life (participation rate, 87.5%) and tolerability (participation rate, 94.7%) were better in the concurrent cisplatin–sparing group, primarily in gastrointestinal, functional, and global health status. Conclusions and Relevance In this phase 3 randomized clinical trial, among patients with locoregionally advanced NPC, toripalimab combination therapy without concurrent cisplatin was a feasible treatment with high efficacy in failure-free survival and low toxicity. Trial Registration ClinicalTrials.gov Identifier: NCT04907370

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsNasopharyngeal CarcinomaNasopharyngeal NeoplasmsVomitingAdultFemaleHumansMaleMiddle AgedChemoradiotherapyCisplatinGemcitabineInduction ChemotherapyImmune Checkpoint InhibitorsFeasibility StudiesChinaFollow-Up StudiesChemotherapy, AdjuvantDisease-Free SurvivalSurvival RateTreatment Failure

Substanzen

Antibodies, Monoclonal, HumanizedCisplatinGemcitabinetoripalimabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial C…
  • Department of Radiation Oncology, Xiangya Hospital of Central South University, Changsha, Hunan, PR China.
  • Department of Oncology, Affiliated Hospital of Guizhou Medical University, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, PR China.
  • Institute of Radiation Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, Hubei, PR China.
  • Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China.
  • Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Guangxi Key Laboratory of Early Prevention and Treatment for Regional High-Incidence-Tumor, Nanning, Guangxi, PR China.

Zitieren

APA

DIAMOND Study Group, Xu, C., Liang, X. Y., Huang, X. Q., Jin, F., Yang, K. Y., Hu, G. Y., Zhu, X. D., Wang, Y., Huang, Y., Zhang, N., Hu, D. S., Guo, L., Zou, G. R., Chen, X. Z., Xiao, S. W., Li, J. G., Shen, L. F., Li, Y. Y., …, & Li, H. J. (2025). Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma. JAMA, 334(11), 973. https://doi.org/10.1001/jama.2025.13205

Vancouver

DIAMOND Study Group, Xu C, Liang XY, Huang XQ, Jin F, Yang KY, et al. Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma. JAMA. 2025;334(11):973. doi:10.1001/jama.2025.13205

BibTeX
@article{DIAMONDStudyGroup2025,
  author = {DIAMOND Study Group, DIAMOND Study Group and Xu, Cheng and Liang, Xiao-Yu and Huang, Xin-Qiong and Jin, Feng and Yang, Kun-Yu and Hu, Guang-Yuan and Zhu, Xiao-Dong and Wang, Ying and Huang, Ying and Zhang, Ning and Hu, De-Sheng and Guo, Ling and Zou, Guo-Rong and Chen, Xiao-Zhong and Xiao, Shao-Wen and Li, Jin-Gao and Shen, Liang-Fang and Li, Yuan-Yuan and Huang, Jing and Long, Guo-Xian and Li, Ling and Huang, Luo and She, Long-Jiang and Wu, Yuan and Zeng, Wei-Hua and Qiang, Meng-Yun and Liu, Wei-Xin and Su, Yong and Tang, Ling-Long and Xie, Fang-Yun and Han, Fei and Lu, Li-Xia and Xiang, Yan-Qun and Mao, Yan-Ping and Li, Wen-Fei and Liu, Xu and Yang, Qi and Zhou, Guan-Qun and Guo, Rui and Ouyang, Pu-Yun and Wang, Xiao-Hui and Chen, Lei and Liu, Li-Ting and Lin, Li and Li, Ji-Bin and Lin, Ai-Hua and Zhao, Hong-Yun and Hong, Shu-Bin and Jie, Yu-Sheng and Huang, Hui-Ling and Tang, Xu-Hua and Zeng, Yue-Can and Yun, Jing-Ping and Zang, Sheng-Bing and Du, Zi-Ming and Ye, Zu-Lu and Liu, Li-Zhi and Tian, Li and Li, Hao-Jiang},
  title = {Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma},
  journal = {JAMA},
  year = {2025},
  volume = {334},
  number = {11},
  pages = {973},
  doi = {10.1001/jama.2025.13205}
}
Kostenlos starten →